Acute cardiac care & resuscitationRandomised controlled trial
Topical Versus Intravenous Tranexamic Acid in Patients Undergoing Cardiac Surgery: The DEPOSITION Randomized Controlled Trial
- Randomised controlled trial
- multicentre
- double dummy
- blinded
- stopped early for safety
- Stopped early for safety on data and safety monitoring board recommendation after the last planned interim analysis (75% of anticipated participants followed up)
Authors' conclusion
Among patients undergoing cardiac surgery, topical administration of tranexamic acid resulted in an 8.3% absolute increase in transfusion without reducing the incidence of seizure, compared with intravenous tranexamic acid.
Study context
- Population
- Patients undergoing cardiac surgery with cardiopulmonary bypass, 16 academic hospitals in 6 countries3,242 randomized (as printed)
- Participants
- 1,624 vs 1,628
- Comparison
- Topical vs intravenous tranexamic acid
- Topicaln = 1,624
- Intravenousn = 1,628reference
- Primary endpoint
- In-hospital seizure
Primary result
As reported in the abstract
Absolute risk difference
−0.5%
95% CI −0.9 to 0.03
P = 0.07
Events by treatment group
Topical vs Intravenous
absolute risk difference −0.5% (95% CI −0.9 to 0.03); P = 0.07
Secondary outcomes
| Outcome | Topical | Intravenous | absolute risk difference (95% CI) | P value | |
|---|---|---|---|---|---|
| Red blood cell transfusion | 35.1% | 26.8% | 8.3% (5.2–11.5) | P = 0.007 | |
| Transfusion of ≥4 units of red blood cells | 8.2% (3.4–12.9) | ||||
| −1001020Difference (linear scale) |
Original publication
Topical Versus Intravenous Tranexamic Acid in Patients Undergoing Cardiac Surgery: The DEPOSITION Randomized Controlled Trial. Circulation. Published 8 April 2024. doi:10.1161/circulationaha.124.069606
Summarised from the published abstract; every number is checked against it